BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tizetatug rezetecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tizetatug rezetecan\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05924256-2726@assetmemo.bio
DTSTAMP:20261121T005941Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tizetatug rezetecan: Phase 2 readout est. (NCT05924256)
DESCRIPTION:Tizetatug rezetecan\, phase 2.\nStudy: A Phase II Study of Adva
 nced Salivary Gland Carcinoma Based on Molecular Typing\nEstimated primary
  completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tizetatug-rezetecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05924256
URL:https://assetmemo.bio/drug/tizetatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433609-2726@assetmemo.bio
DTSTAMP:20261121T005941Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tizetatug rezetecan: Phase 2 readout est. (NCT06433609)
DESCRIPTION:Tizetatug rezetecan\, phase 2.\nStudy: Study of ADCs Combined W
 ith Adebrelimab in HER2-negative Advanced Breast Cancer\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tizetatug-rezetecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06433609
URL:https://assetmemo.bio/drug/tizetatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06480136-2726@assetmemo.bio
DTSTAMP:20261121T005941Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:Tizetatug rezetecan: Phase 2 readout est. (NCT06480136)
DESCRIPTION:Tizetatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCL
 C Who Failed the Previous Standard First-line Treatment\nEstimated primary
  completion: 15 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tizetatug-rezetecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06480136
URL:https://assetmemo.bio/drug/tizetatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2726@assetmemo.bio
DTSTAMP:20261121T005941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tizetatug rezetecan: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Tizetatug rezetecan\, phase 2.\nStudy: Fudan University Shangha
 i Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant
  Therapy\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tizetatug-rezetecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/tizetatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474455-2726@assetmemo.bio
DTSTAMP:20261121T005941Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tizetatug rezetecan: Phase 1/2 readout est. (NCT06474455)
DESCRIPTION:Tizetatug rezetecan\, phase 1/2.\nStudy: A Phase IB/II Clinical
  Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies 
 in Patients With Advanced Solid Tumors\nEstimated primary completion: June
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tizetatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06474455
URL:https://assetmemo.bio/drug/tizetatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
